BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/18/2022 8:29:59 AM | Browse: 373 | Download: 792
 |
Received |
|
2022-08-12 11:46 |
|
Peer-Review Started |
|
2022-08-12 11:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-08-29 07:33 |
|
Revised |
|
2022-09-06 09:51 |
|
Second Decision |
|
2022-09-19 03:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-09-19 17:00 |
|
Articles in Press |
|
2022-09-19 17:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-09-30 09:44 |
|
Typeset the Manuscript |
|
2022-10-11 00:10 |
|
Publish the Manuscript Online |
|
2022-10-18 08:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Panagiotis Theofilis, Aikaterini Vordoni and Rigas G Kalaitzidis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Panagiotis Theofilis, MD, Doctor, Doctor, Researcher, Center for Nephrology “G. Papadakis”, General Hospital of Nikaia-Piraeus “Agios Panteleimon”, Piraeus , Nikaia 18454, Greece. panos.theofilis@hotmail.com |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; Chronic kidney disease; Hepatic steatosis; inflammation; Type 2 diabetes mellitus; Obesity |
| Core Tip |
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a recently defined pathological state aiming to identify individuals at increased risk of adverse prognosis. Numerous epidemiological studies propose that chronic kidney disease may be among its complications. Their shared risk factors, molecular mechanisms, and genetic predisposition represent the basis for this relationship. Accordingly, treatment approaches with combined efficacy in MAFLD and chronic renal impairment are expected to positively impact the natural history of this deleterious interaction, which remains to be confirmed in future studies. |
| Publish Date |
2022-10-18 08:29 |
| Citation |
Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i39/5691.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i39.5691 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
